RSV/hMPV Vaccine for Respiratory Syncytial Virus Immunization

Not currently recruiting at 21 trial locations

Overseen By Trial Transparency email recommended (Toll free for US & Canada)

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Sanofi Pasteur, a Sanofi Company

Must not be taking: Immunosuppressants, Corticosteroids, Anticoagulants, others

Disqualifiers: Immunodeficiency, Myocarditis, Thrombocytopenia, others

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new vaccine for two viruses, hMPV and RSV, which can cause lung problems in older adults. Researchers aim to determine if the vaccine is safe and effective in helping the body combat these viruses. Participants will receive the vaccine through a single injection and will be monitored over several months. The trial seeks individuals aged 60 and older who haven't recently contracted these viruses and aren't on certain medications. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new vaccine.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or long-term systemic corticosteroids, you may not be eligible to participate.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that mRNA vaccines, like the one being tested for RSV and hMPV, have been safe in past studies. For instance, an mRNA vaccine for hMPV was well tolerated by healthy adults, with most experiencing no serious side effects.

Additionally, an approved RSV mRNA vaccine for older adults has demonstrated safety and effectiveness. This suggests that the hMPV/RSV mRNA vaccine could also be safe, as it uses similar technology and methods.

These vaccines are designed to help the body's immune system recognize and fight viruses without causing harm. While this trial will provide more specific safety information, past experiences with similar vaccines are promising. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Unlike standard RSV treatments, which often involve monoclonal antibodies or traditional protein-based vaccines, the hMPV/RSV mRNA vaccine uses cutting-edge mRNA technology. This approach allows the vaccine to instruct cells to produce specific viral proteins, triggering an immune response without using the live virus. Researchers are excited about mRNA vaccines because they can be rapidly developed and adapted, potentially providing broader protection and faster responses to emerging virus strains. Additionally, the mRNA platform has shown a strong safety profile and effectiveness in other vaccines, such as those for COVID-19, which fuels optimism for its application in RSV and hMPV prevention.

What evidence suggests that this trial's treatments could be effective for preventing lower respiratory tract disease?

This trial will evaluate different formulations of an investigational mRNA vaccine for RSV and hMPV. Studies have shown that mRNA vaccines for RSV and hMPV can create strong immune responses in adults aged 60 to 75, helping the body recognize and fight these viruses. Research indicates that vaccines like those tested in this trial have been safe and well-tolerated in other studies, suggesting they can effectively protect against illnesses caused by these viruses. In some cases, similar vaccines demonstrated an effectiveness rate of about 86.7% against RSV infections in adults. This high percentage highlights the vaccine's potential to prevent symptoms, offering promising protection for older adults. ^{1 3 6 7 8}

Are You a Good Fit for This Trial?

This trial is for adults aged 60 and older who are not pregnant or breastfeeding. Women must be postmenopausal for at least a year or surgically sterile to participate. The study aims to prevent lower respiratory tract disease caused by hMPV/RSV.

Inclusion Criteria

Are you 60 years old or older?

Exclusion Criteria

Do you have an autoimmune disorder or are you on any immunosuppressive medication?

Have you ever experienced a severe allergic reaction to a vaccine?

Have you ever been diagnosed with or received vaccination for RSV (respiratory syncytial virus)?

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment - Stage 1 Sentinel Cohort

Participants receive 1 intra-muscular (IM) injection and are followed for 6 months post-vaccination

6 months

Treatment - Stage 1 Main Cohort

Participants receive 1 IM injection and are followed for 6 months post-vaccination

6 months

Treatment - Stage 2 Expansion Cohort

Participants receive 1 IM injection; selected formulation arm followed for 12 months, others for 8 months post-vaccination

8-12 months

Booster - Stage 2 Booster Cohort

Participants receive 1 IM injection 12 months post-primary vaccination and are followed for 12 months post-booster

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• hMPV/RSV mRNA Vaccine

Trial Overview

The study tests the safety and immune response of an mRNA vaccine candidate targeting human metapneumovirus (hMPV) and respiratory syncytial virus (RSV), comparing it with a placebo, licensed RSV vaccine, and other investigational vaccines.

How Is the Trial Designed?

Group I: Group X Stage 2 Expansion Cohort Experimental Treatment 1 Intervention

1 IM injection of selected investigational hMPV/RSV vaccine formulation from Group 1-9 of Stage 1 Main Cohort

Group II: Group B Stage 1 Sentinel Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation B

Group III: Group A Stage 1 Sentinel Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation A

Group IV: Group 9 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation I

Group V: Group 8 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation H

Group VI: Group 7 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation B

Group VII: Group 6 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation A

Group VIII: Group 5 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation G

Group IX: Group 4 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation F

Group X: Group 3 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation E

Group XI: Group 2 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation D

Group XII: Group 15 Stage 2 Booster Cohort Experimental Treatment 2 Interventions

1 IM injection of investigational RSV + hMPV vaccine formulation administered to participants from Group 14 of Expansion Cohort

Group XIII: Group 14 Stage 2 Expansion Cohort Experimental Treatment 1 Intervention

1 IM injection of licensed RSV vaccine

Group XIV: Group 13 Stage 2 Expansion Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV monovalent vaccine

Group XV: Group 12 Stage 2 Expansion Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational RSV monovalent vaccine

Group XVI: Group 10 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation J

Group XVII: Group 1 Stage 1 Main Cohort Experimental Treatment 1 Intervention

1 IM injection of investigational hMPV/RSV vaccine formulation C

Group XVIII: Group C Stage 1 Sentinel Cohort Placebo Group 1 Intervention

1 IM injection of placebo

Group XIX: Group 11 Stage 1 Main Cohort Placebo Group 1 Intervention

1 IM injection of placebo

Who Is Running the Clinical Trial?

Sanofi Pasteur, a Sanofi Company

Lead Sponsor

Trials

429

Recruited

6,140,000+

Paul Hudson

Sanofi Pasteur, a Sanofi Company

Chief Executive Officer since 2019

Degree in Economics from Manchester Metropolitan University

Dr. Thomas Triomphe

Sanofi Pasteur, a Sanofi Company

Chief Medical Officer since 2020

MD from Tehran University of Medical Sciences

Published Research Related to This Trial

A recombinant Sendai virus (SeV) carrying a gene for a truncated hMPV fusion protein was developed, showing promise as a vaccine against human metapneumovirus (hMPV) infections, particularly in vulnerable young children.

The vaccine successfully induced binding and neutralizing antibody responses and provided protection against hMPV in a cotton rat model, suggesting its potential for preventing serious health risks associated with hMPV infections.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Russell, CJ., Jones, BG., Sealy, RE., et al.[2018]

The investigational RSV vaccine ChAd155-RSV was well-tolerated in healthy adults aged 18-45, with no dose-related toxicity or serious adverse events observed during a 1-year follow-up.

ChAd155-RSV effectively increased specific immune responses, including neutralizing antibodies and T-cell activity, indicating its potential efficacy in generating protection against RSV.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. Cicconi, P., Jones, C., Sarkar, E., et al.[2022]

A novel vaccine candidate, b/h PIV3/hMPV F2, was engineered and shown to generate strong immune responses in African green monkeys, providing protection against human metapneumovirus (hMPV) infection.

The vaccine demonstrated safety and attenuation in rhesus monkeys, indicating its potential for further evaluation in humans to prevent hMPV-related respiratory diseases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Tang, RS., Mahmood, K., Macphail, M., et al.[2020]

Respiratory syncytial virus (RSV) poses a significant health risk not only to infants but also to older adults, prompting urgent vaccine development efforts, with 19 candidates currently in clinical trials.

Advancements in understanding the RSV surface fusion glycoprotein have led to innovative vaccine strategies, including particle-based, live-attenuated, subunit, and vector-based approaches, although past trial failures indicate the need for improved knowledge on immunological protection.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Mazur, NI., Higgins, D., Nunes, MC., et al.[2023]

The study evaluated recombinant murine pneumonia virus (rMPV) as a potential vaccine vector for respiratory syncytial virus (RSV), demonstrating that it can effectively express the RSV F protein and induce high levels of neutralizing antibodies in rhesus macaques.

rMPV showed low levels of replication in the respiratory tracts of the macaques while maintaining stable expression of the RSV F protein, suggesting it could be a safe and immunogenic vaccine candidate for both RSV-naive and RSV-experienced populations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques. Brock, LG., Liu, X., Liang, B., et al.[2019]

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infections in infants and the elderly, and despite its prevalence, there is currently no licensed vaccine available.

Promising vaccine candidates are in development, with nanoparticle and subunit vaccines showing potential for pregnant women and the elderly, while live-attenuated or vector-based vaccines may be more suitable for children.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Respiratory syncytial virus vaccines: an update on those in the immediate pipeline. Esposito, S., Di Pietro, G.[2020]

Human metapneumovirus (HMPV) is a significant cause of respiratory infections in infants, and despite extensive research, no effective vaccines for HMPV or respiratory syncytial virus (RSV) have been developed in over 50 years.

Recombinant chimeric viruses that express antigens from HMPV and other viruses show promise as potential vaccine candidates, with ongoing studies validating their effectiveness and suggesting optimization strategies based on RSV research.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Engineering of Live Chimeric Vaccines against Human Metapneumovirus. Ogonczyk Makowska, D., Hamelin, MÈ., Boivin, G.[2020]

The bivalent RSVpreF vaccine was found to be safe and well-tolerated in a study of 618 adults aged 18-49, with mostly mild or moderate local and systemic reactions and no serious adverse events reported within 12 months post-vaccination.

The vaccine induced strong virus-neutralizing responses, with antibody levels significantly higher than those needed for protection in high-risk infants, suggesting its potential effectiveness for maternal immunization against RSV.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. Walsh, EE., Falsey, AR., Scott, DA., et al.[2022]

The mRNA-1345 vaccine demonstrated high efficacy, with 83.7% effectiveness in preventing RSV-associated lower respiratory tract disease with at least two symptoms, and 68.4% efficacy against RSV-associated acute respiratory disease in a study involving 35,541 older adults.

The vaccine was generally safe, with most adverse reactions being mild to moderate and transient, although there was a higher incidence of local and systemic reactions compared to the placebo group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. Wilson, E., Goswami, J., Baqui, AH., et al.[2023]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40201719/

A Randomized Phase 1 Clinical Trial of a Respiratory ...

Conclusions: IVX-A12 was well-tolerated and elicited RSV- and hMPV-specific antibody responses in adults 60-75 years of age. These data support ...

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06686654

NCT06686654 | Study of a Human Metapneumovirus ...

The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate.

3.

fda.gov

fda.gov/media/184378/download

Moderna Final

Moderna's RSV vaccine (mRESVIA) is licensed for use in adults ≥60 years of age. ▫. Safety and efficacy demonstrated in global study of ...

4.

mdpi.com

mdpi.com/2076-393X/13/6/569

Vaccine Development for Human Pneumoviruses

Phase 2 evaluations revealed an efficacy of 86.7% in preventing symptomatic RSV infections in adults in a challenge study [155] and efficient transplacental ...

5.

journals.plos.org

journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013312

A second-generation molecular clamp stabilised bivalent ...

As with RSV, the hMPV preF has been demonstrated to elicit a higher neutralising immune response than hMPV postF [21–24], however there are also some ...

6.

sanofistudies.com

sanofistudies.com/cwout/CW-V9DEXS//au/en/listing/312907/study-of-the-safety/

Study of an Investigational Vaccine for Respiratory Viruses ...

This study investigates an investigational vaccine designed to prevent lower respiratory tract disease caused by respiratory syncytial virus ...

7.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9251669/

Safety and Immunogenicity of an mRNA-Based Human ...

mRNA-1653 was well tolerated, with an acceptable safety profile and increased hMPV and PIV3 neutralization titers in healthy adults.

8.

journals.lww.com

journals.lww.com/ijsoncology/fulltext/9900/emerging_and_reemerging_human_metapneumovirus.31.aspx

Emerging and reemerging human metapneumovirus (hMPV)

Safe and effective mRNA hMPV vaccine development with LNP-based delivery strategy. The development of a multi-epitope vaccine simultaneously ...